Latigo Biotherapeutics Inc.
Latigo Biotherapeutics Inc.
- Market cap
- $781.99M
Your view on LTGO
Overview
What the company does, where it operates, and who runs it.
About Latigo Biotherapeutics Inc.
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Nima Farzan
- Headquarters
- 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oak, CA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Nima Farzan
- Headquarters
- 1300 Rancho Conejo Boulevard, Suite 305, Thousand Oak, CA, US
Latigo Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing innovative non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its products include Molecule: LTG-001, Molecule: LTG-32, Molecule: LTG-001 IV and Molecule: LTG-418.
The company was founded on November 20, 2018 and is headquartered in Thousand Oak, CA.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Latigo Biotherapeutics Inc.. Starting points for Latigo Biotherapeutics Inc.: EPS -$2.84 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Latigo Biotherapeutics Inc.. Trailing twelve-month EPS for Latigo Biotherapeutics Inc. stands at -$2.84. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Latigo Biotherapeutics Inc.. Latigo Biotherapeutics Inc. has reported as a listed company since 2026. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| ORXOYOrexo AB (publ) | Healthcare | OTC | $102.7M | ||
| OVITOncoVista Innovative Therapies, Inc. | Healthcare | OTC | $2,356 | ||
| OXIHFOxford Investments Holdings Inc. | Healthcare | OTC | $71,958 | ||
| PAVSParanovus Entertainment Technology Ltd. | Healthcare | NASDAQ | $2.0M | ||
| PBHPrestige Consumer Healthcare Inc. | Healthcare | NYSE | $2.4B | ||
| PKBFFPeakBirch Commerce Inc. | Healthcare | OTC | $544.7M | ||
| PLWYPeoplesway.com Inc. | Healthcare | OTC | $1,508 | ||
| PNDHFPond Technologies Holdings Inc. | Healthcare | OTC | $684,738 | ||
| PNPLPineapple, Inc. | Healthcare | OTC | $5.6M | ||
| POMPOMDOCTOR Ltd | Healthcare | NASDAQ | $14.6M | ||
| PRPHProPhase Labs, Inc. | Healthcare | NASDAQ | $331,590 | ||
| PXYNPraxsyn Corporation | Healthcare | OTC | $6,347 | ||
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by Latigo Biotherapeutics Inc. executives and directors. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Latigo Biotherapeutics Inc.. Coverage tracks Latigo Biotherapeutics Inc. within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.
Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Latigo Biotherapeutics Inc.